Kentucky gets OK to dismantle state exchange site

Another state is moving to the federal Healthcare.gov marketplace rather than running its own exchange, after Kentucky has been given permission to shut down kynect, its state-run site.

The Louisville Courier-Journal reported Gov. Matt Bevin had called the state exchange redundant and made it a pledge in his 2015 campaign to dismantle the site. While approving the move to the federally-facilitated marketplace, CMS Acting Administrator Andy Slavitt did worry that change would cause “confusion.”

“We remain concerned that kynect's transition to the federal platform may disrupt the seamless system of coverage that kynect established," Slavitt said in a letter to Bevin.

Bevin’s administration, however, said the switch won’t disrupt customers shopping for coverage when open enrollment begins in November.

“This transition will allow Kentucky to achieve substantial cost-savings while still allowing citizens to enroll in qualified health plans," said governor’s office spokesperson Amanda Stamper.

For more on the transition, and how Bevin’s predecessor fought to keep the exchange even after losing an election, click on the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.